Leveraging the huge domestic antibiotic market and our leading status in the antibiotic industry, CR Gosun is actively expanding strategic cooperation with transnational counterparts and foreign professional pharmaceutical companies, in order to achieve mutual advantage complementation. It is devoted to providing innovative anti-infective products and solutions with high safety and high efficacy and high value with clinical demands as a guide by focusing on resistant bacteria, fungi and influenza virus, and to deal with public health and safety challenges mutually
l Gosun is a leading pharmaceutical company in China market for decades
CR Gosun has been engaged in the field of anti-infection for thirty years, with overall sale amount and core products, including Xin Tai Lin®, Jia Mei Shu® and Mei Hong® all ranking top in the anti-infection market.
l Gosun has a diverse product portfolio
The company has rich combination of various products, and the dosage forms include lyophilized powder, powder injection and oral solid preparations. The injection preparations include Xin Tai Lin® (Cefazolin Sodium Pentahydrate for Injection), Cefotaxime Sodium for Injection, Ceftazidime for Injection and etc.; and oral preparations include Jia Mei Shu® (Azithromcin Enteric-coated Capsules), Mei Hong® (Erythromycin Enteric-coated Capsules) and etc.
Gosun has strong strength especially in the area of cephalosporins, the related products cover 1-5 generations, and the exclusively technology licensed product, Zevtera®, is the first approved cephalosporin of the fifth generation in China, which can meet clinical treatment demands for resistant bacteria and provide a new treatment solution for patients.
l Gosun has abundant customer and end resources
The company possesses a self-supporting matured team for investment promotion, and has established a good academic resource platform. Our products cover various hospitals at provincial, municipal and county levels across China.